Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIGATOR: Nateglinide and Valsartan in IGT for Diabetes and CV Prevention
NCT00097786Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2002
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 38
01
Overview
A Phase 3 trial of valsartan, nateglinide in type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), sponsored by Novartis. Started Jan 2002; status: completed.
02
Drugs
valsartannateglinide
03
Conditions
type 2 diabetes mellitus (T2DM)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00097786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097786.